A Clinical Study of CD19 Chimeric Antigen Receptor T-Cell Therapy for Patients With Refractory Childhood-Onset Systemic Lupus Erythematosus
This study is evaluating the safety and potential benefits of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in children and young adults with severe systemic lupus erythematosus (SLE) that began during childhood. The study will include up to 8 participants aged 25 years or younger whose disease remains active despite treatment with multiple immune-suppressing medicines and has affected at least one major organ. CAR-T cells will be made from each participant's own T cells and modified to recognize CD19, a protein found on B cells that contribute to SLE. Participants will receive chemotherapy to reduce existing immune cells, followed by a single intravenous infusion of SNUH-CD19-CAR-T cells. They will be monitored for side effects and changes in disease activity, organ involvement, laboratory findings, and the need for steroids or other immune-suppressing medicines. The main assessment will be performed 1 year after the CAR-T cell infusion.
• Participants must be 25 years of age or younger at the time of SNUH-CD19-CAR-T infusion.
• Participants must have a diagnosis of systemic lupus erythematosus and meet the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology classification criteria for systemic lupus erythematosus.
• Participants must be currently receiving or have previously received at least three of the following therapies, including corticosteroids: hydroxychloroquine, methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine, tacrolimus, rituximab, or belimumab.
• Participants must have involvement of at least one of the following major organ systems:
‣ Kidney: class II-V lupus nephritis confirmed by biopsy or proteinuria greater than 0.5 g/day
⁃ Heart: pericarditis, myocarditis, conduction abnormality, or valvular disease
⁃ Lung: pleuritis, interstitial lung disease, or pulmonary arterial hypertension
⁃ Hematologic system: platelet count below 50,000/μL or hemolytic anemia
• Participants must have uncontrolled active disease, defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 10 or higher.